 |
ABSTRACT SUBMISSION
Poster abstract deadline 3 April 2006
You may submit your abstract to the Organising Secretariat:
By email to espanol@esoncology.org
or online at: www.cnio.es/meetings
By CD-ROM to Beatriz Ferreiro, Centro Nacional de Investigaciones
Oncológicas, Melchor Fernández Almagro, 3; E-28029 Madrid
Spain (ref: Familial Cancer)
Instructions for abstract submission
Participants with new data relevant to the subject of the conference may submit
one
abstract to be considered for poster presentation. Only papers whose abstracts
have
been reviewed and approved by the conference co-ordinator will be presented.
Abstracts should be written in English and the text should not exceed 2000 characters
(title included).
The title should appear in capital letters.
For each author, type surname first, followed by first name and initials (presenting
author in capital letters).
List affiliations after the author's list.
Indicate 3-5 keywords at the end of the text.
The full address with telephone, fax number and email of the corresponding author
must be provided. This author will receive all the subsequent communication
concerning this abstract.
Please also indicate your approval for publication in case the abstracts are
issued in a
journal.
Please note: Only abstracts submitted by registered participants
will be accepted.
Please do not forget to mark on the registration form that you have submitted
an
abstract.
It is the responsibility of the presenting author to ascertain whether all authors
are
aware of the content of the abstract before submission.
15 JUNE
09.00 Welcome
CONCEPTS IN FAMILIAL CANCER GENETICS
Chair: G. Romeo, IT
09.15 Genetic predisposition, familial cancer clustering, hereditary cancer
syndromes
J. Benítez, ES
09.35 Familial cancer epidemiology: common and rare inherited cancer syndromes,
family
cancer database J. Lubinski, PL
09.55 Modifier factors D. Goldgar, US
10.15 Technical approaches USV M. Robledo, ES
10.35 Coffee break
11.00 Genetic counselling M. Urioste, ES
11.20 Psychological impact P. Gil, ES
11.40 Ethical issues of genetic testing P. Nicolás, ES
12.00 Round table
INHERITED BREAST AND OVARIAN CANCER SYNDROMES
Chair: A. Osorio, ES
12.20 Genetic epidemiology T. Caldés, ES
12.40 Histopathology of BRCA1/2 tumours J. Palacios, ES
13.00 Lunch
INHERITED BREAST AND OVARIAN CANCER SYNDROMES (Continuation)
14.30 The Fanconi anaemia/BRCA pathway: from chromosome fragility to cancer
predisposition J. Suralles, ES
14.50 Selection criteria and management choices in high risk families D. Eccles,
UK
15.10 Early detection, screening options in women at high risk R. Eeles, UK
15.30 Experimental therapy, new targets P. Harris, UK
15.50 Round table
16.15 Coffee break
POSTER SESSION *
Chair: D. Eccles, UK - T. Caldés, ES
16.45 - Oral presentation of selected posters (5') (maximum 5 slides)
18.00 * Posters will be selected by the chair.
16 JUNE
COLORECTAL CANCER
Chair: I. Blanco, ES
09.00 Molecular biology of hereditary nonpolysposis colorectal cancer (HNPCC).
The mistmach repair genes L. Aaltonen, FI
09.20 The genetics of APC. Clinical diagnosis and genetic screening P. Radice,
IT
09.40 Other colorectal cancer susceptibility genes H. Thomas, UK
10.00 Management of patients with colorectal cancer H. Vasen, NL
10.20 Round table
10.40 Coffee break
OTHER INHERITED CANCER SYNDROMES
Chair: J. Lubinski, PL
11.10 Genetics of endocrine tumours G. Romeo, IT
11.30 Tuberous sclerosis. Clinical and genetic diagnosis J. Sampson, UK
11.50 Renal tumours Maher, UK
12.10 PTEN syndromes. Clinical and genetic spectrum J. Merks, NL
12.30 Familial melanoma F. Demenais, FR
12.50 Round table
13.10 Lunch
NEW APPROACHES
Chair: .J. Benítez, ES
14.30 The search for new genes: prostate S. Tavtigian, FR
14.50 Expression profiles by cDNA arrays, genes predictors of survival A. Osorio,
ES
15.10 New perspectives for early diagnosis. Ductal lavage I. Locke, UK
15.30 Animal models: the XP mouse model M. Blasco, ES
15.50 Round table
16.10 Coffee break
PRESENTATION OF CLINICAL CASES AND FAMILIES
Chair: P. Radice, IT
16.30 Complex cases for discussion -submission of cases from speakers and examples
from
from the faculty I. Blanco, ES - R. Eeles, UK - H. Vasen, NL
18.00 Closing remarks
INVITED FACULTY
L. Aaltonen University of Helsinki, FI
J. Benítez Centro Nacional de Investigaciones Oncológicas,
Madrid, ES
I. Blanco Catalonian Institute of Oncology (ICO), Barcelona,
ES
M. Blasco Centro Nacional de Investigaciones Oncológicas,
Madrid, ES
T. Caldés Hospital Universitaria san Carlos, Madrid,
ES
F. Demenais INSERM, Université d'Evry, Evry, FR
D. Eccles Southampton General Hospital, UK
R. Eeles Institute for Cancer Research, Royal Marsden NHS Trust,
Sutton, UK
P. Gil Catalonian Institute of Oncology (ICO), Barcelona, ES
D. Goldgar University of Utah, Salt Lake City, US
P. Harris Kudos Pharmaceuticals Ltd., Cambridge, UK
I. Locke Institute of Cancer Research and The Royal Marsden
NHS Trust, Sutton, UK
J. Lubinski Pomeranian Medical University, PL
E.R. Maher University of Birmingham, UK
J. Merks Emma Children’s Hospital/Academic Medical Center,
Amsterdam, NL
P. Nicolás Catedra Interuniversitaria Fundación
BBVA, Bilbao, ES
A. Osorio Centro Nacional de Investigaciones Oncológicas,
Madrid, ES
J. Palacios Centro Nacional de Investigaciones Oncológicas,
Madrid, ES
P. Radice Istituto Nazionale per lo Studio e la Cura dei Tumori,
Milan, IT
M. Robledo Centro Nacional de Investigaciones Oncológicas,
Madrid, ES
G. Romeo University of Bologna, IT
J. Sampson Cardiff University, UK
J. Suralles Autonomous University of Barcelona, ES
S. Tavtigian International Agency for Research on Cancer (IARC),
Lyon, FR
H. Thomas St. Mark's Hospital, London, UK
M. Urioste Centro Nacional de Investigaciones Oncológicas,
Madrid, ES
H. Vasen Leiden University Medical Centre, NL
Más
información
|
|
